Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Alphamab Oncology Secures $2.2B Deal with Pathos AI for JSKN016 Global Licensing

Fineline Cube Aug 5, 2026
Company Deals

Hunan Zonsen PepLib Biotech Secures Over RMB 300 Million in Series C Financing

Fineline Cube Aug 5, 2026
Company Deals

Siemens Healthineers and Cleveland Clinic Announce 10-Year Strategic Partnership

Fineline Cube Aug 4, 2026
Company Deals

Apeloa Pharmaceutical and METiS Therapeutics Announce Strategic CDMO Partnership

Fineline Cube Aug 4, 2026
Company Deals

ELI Radiopharma and United Imaging Research Institute Forge Strategic Alliance to Advance Radiopharmaceutical Innovation

Fineline Cube Aug 4, 2026
Drug Medical Device Policy / Regulatory

NMPA Proposes Framework for Synchronized Development of Anti-Tumor Drugs and Companion Diagnostics

Fineline Cube Aug 4, 2026
Company Drug

CARsgen Therapeutics’ CT0596 Receives NMPA Clinical Approval for Relapsed/Refractory Multiple Myeloma

Fineline Cube Aug 5, 2026
Company Drug

InnoCare Pharma’s Orelabrutinib-Mesutoclax Combination Receives Breakthrough Therapy Designation for Marginal Zone Lymphoma

Fineline Cube Aug 5, 2026
Company Drug

Merck’s Welireg Launched in China for Rare Genetic Disorder Treatment

Fineline Cube May 23, 2025

US-based Merck, Sharp & Dohme (MSD; NYSE: MRK) announced the commercial launch of its hypoxia-inducible...

Company Drug

NMPA Approves Bayer/Regeneron’s Eylea HD for Wet AMD Treatment

Fineline Cube May 23, 2025

China’s National Medical Products Administration (NMPA) has approved Bayer (ETR: BAYN) and Regeneron’s (NASDAQ: REGN)...

Company Drug

Ascentage Pharma to Present Data on Lisaftoclax and Alrizomadlin at ASCO 2025

Fineline Cube May 23, 2025

China-based Ascentage Pharma (NASDAQ: AAPG, HKG: 6855) will present the latest data from two ongoing...

Company Deals

Meinian Onehealth Partners with Alibaba DAMO Academy for AI-Driven Disease Screening

Fineline Cube May 23, 2025

China-based Meinian Onehealth Healthcare (Group) Co., Ltd (SHE: 002044) has entered into a partnership with...

Company Deals

Lead Healthcare Raises RMB 100M in Angel Financing to Boost AI-Driven Life Science Instruments

Fineline Cube May 23, 2025

China-based Lead Healthcare Technology (Guangzhou) Co., Ltd reportedly raised close to RMB 100 million (USD...

Company Deals

WinHealth Pharma Expands Long-Term Partnership with Merz Therapeutics

Fineline Cube May 23, 2025

China-based Hong Kong WinHealth Pharma Group this week formally entered into a long-term partnership with...

Company Deals

Servier Acquires BioNova’s BN104 for Acute Leukemia Treatment

Fineline Cube May 23, 2025

French pharmaceutical firm Servier announced a definitive agreement to acquire BN104 from BioNova Pharmaceuticals (Shanghai)...

Company Drug

ImmuneOnco and Instil Bio Announce Clinical Updates for IMM2510 in NSCLC

Fineline Cube May 23, 2025

China-based ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) and its US partner Instil Bio Inc...

Company Drug Policy / Regulatory

UCB’s Keppra Procurement Resumed in Shanghai After Regulatory Halt

Fineline Cube May 23, 2025

Shanghai’s Sunshine Medical Procurement All-in-One (SMPA) has issued a notification resuming the procurement of UCB’s...

Company Deals

RemeGen Plans Hong Kong Share Placement to Fund Telitacicept Expansion

Fineline Cube May 23, 2025

China-based biopharma RemeGen Ltd (HKG: 9995) announced plans to place 10.2% of its issued shares...

Company Drug

Ascletis Pharma Starts Phase I Study of ASC50 for Psoriasis in the US

Fineline Cube May 23, 2025

China-based Ascletis Pharma Inc. (HKG: 1672) announced that it has received approval from the US...

Company Drug

Jacobio Pharma’s Glecirasib Approved by NMPA for KRAS G12C+ NSCLC

Fineline Cube May 23, 2025

China-based Jacobio Pharma (HKG: 1167) announced that it has received marketing approval from the National...

Company

AstraZeneca Shuts Down Neuroscience Research Group to Focus on Core Areas

Fineline Cube May 23, 2025

AstraZeneca (AZ; NASDAQ: AZN) confirmed the closure of its neuroscience research group during its 2025...

Company Drug

Hengrui Pharmaceuticals’ Retagliptin and Metformin Approved by NMPA for Type 2 Diabetes

Fineline Cube May 23, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced that it has received marketing...

Company Drug

Roche’s Susvimo Gets FDA Approval for Diabetic Retinopathy

Fineline Cube May 23, 2025

Swiss giant Roche (SWX: ROG, OTCMKTS: RHHBY) announced that its Susvimo (ranibizumab) 100mg/mL intravitreal ocular...

Company Deals

Joincare Pharmaceutical Plans to Acquire 64.81% Stake in Imexpharm for USD 220M

Fineline Cube May 23, 2025

China-based Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380) announced plans to acquire a 64.81%...

Company Drug

Chongqing Genrix Bio’s GR2001 Tetanus Monoclonal Antibody NDA Accepted by NMPA

Fineline Cube May 23, 2025

China-based Chongqing Genrix Bio Pharmaceutical Co., Ltd (SHA: 688443) recently announced that its New Drug...

Company Medical Device

Medtronic Plans to Spin Off Diabetes Business into Publicly Traded Entity

Fineline Cube May 23, 2025

Medtronic plc (NYSE: MDT), the US-headquartered medical technology company, has unveiled plans to spin off...

Company Drug

Bayer Launches Phase I Study of BAY 3670549 for Atrial Fibrillation

Fineline Cube May 23, 2025

German pharmaceutical giant Bayer (ETR: BAYN) this week initiated a Phase I clinical study for...

Company Drug

InnoCare Pharma’s Minjuvi Gains NMPA Approval for DLBCL Treatment

Fineline Cube May 23, 2025

China-based InnoCare Pharma (HKG: 9969, SHA: 688428) announced that the National Medical Products Administration (NMPA)...

Posts pagination

1 … 194 195 196 … 703

Recent updates

  • AbbVie Reports 10.2% Revenue Growth in Q2 2026, Driven by Strong Immunology Performance
  • WuXi AppTec Reports 38.9% Revenue Growth in H1 2026, Raises Full-Year Guidance
  • Alphamab Oncology Secures $2.2B Deal with Pathos AI for JSKN016 Global Licensing
  • Hunan Zonsen PepLib Biotech Secures Over RMB 300 Million in Series C Financing
  • CARsgen Therapeutics’ CT0596 Receives NMPA Clinical Approval for Relapsed/Refractory Multiple Myeloma
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company

AbbVie Reports 10.2% Revenue Growth in Q2 2026, Driven by Strong Immunology Performance

Company

WuXi AppTec Reports 38.9% Revenue Growth in H1 2026, Raises Full-Year Guidance

Company Deals

Alphamab Oncology Secures $2.2B Deal with Pathos AI for JSKN016 Global Licensing

Company Deals

Hunan Zonsen PepLib Biotech Secures Over RMB 300 Million in Series C Financing

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.